CD8A and neoplasm: Our earlier studies indicate the anti-tumor efficacies of both ESC cell-based or exosome-based vaccines were correlated with significantly enhanced T cell-mediated immune responses, including potent Th1-mediated cytokine responses in splenic CD8+ T cells and higher CD8+ T/Tregs cell ratio in tumors3,11.